Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity.
Yang WangBing XiaLixia CaoJianfeng YangCui FengFangdun JiangChen LiLixia GuYifan YangJing TianXin ChengKeiji FuruuchiJames FulmerArielle VerdiKatherine RybinskiAllis SotoEarl AlboneToshimitsu UenakaLikun GongTingting LiuQiuping QinZiping WeiYuhong ZhouPublished in: Antibody therapeutics (2024)
The preclinical data support the test of BB-1701 in patients with various HER2-expressing cancers, including those resistant to other HER2-targeting ADCs. A phase I clinical trial of BB-1701 (NCT04257110) in patients is currently underway.
Keyphrases
- growth factor
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- cancer therapy
- chronic kidney disease
- recombinant human
- phase ii
- peritoneal dialysis
- electronic health record
- stem cells
- magnetic resonance
- randomized controlled trial
- big data
- machine learning
- magnetic resonance imaging
- computed tomography
- study protocol
- patient reported outcomes
- diffusion weighted imaging
- anti inflammatory
- data analysis
- contrast enhanced